PreciDIAB

The European Metropolis of Lille, the Lille University Hospital, the University of Lille and Eurasanté are joining forces within the framework of a large-scale partnership for health research in the region

The European Metropolis of Lille (MEL), the University Hospital of Lille, the University of Lille and Eurasanté work together to meet the public health challenges of the population by supporting research projects of excellence, spearheads of the innovation and health research in Lille.

Responding to the MEL’s Metropolitan Higher Education and Research Scheme, and to the strategic orientations of each of the stakeholders, these projects will be financed in part thanks to a MEL grant voted during the Metropolitan Council of June 15, amounting to initially, to 1.810 million euros.

“The association of our institutions in these large-scale projects for the territory is a unique opportunity. It allows us to unite our wills and our means, in order to develop innovations of excellence in the service of the care of patients at the Lille University Hospital. It is also the mark of a strong commitment, affirming our determination to succeed in our joint application for the IHU PreciDIAB, a project which is fully in line with the missions and ambitions of the Lille University Hospital as a major player. care, research and training ”. Frédéric Boiron, Director General of the Lille University Hospital

The first two projects consist of the creation of a clinical trial unit (CTU) and a University Hospital Chair of Excellence to accommodate a high-level researcher. They are part of the Lille ambition to create the PreciDIAB Institute Hospitalo ‐ Universitaire (IHU), bringing together researchers, clinicians, teachers and industrialists, and aiming to rethink the health and care pathway of the diabetic patient by relying on the tools of precision medicine. Submitted in December 2017, the PreciDIAB dossier was preselected among 17 projects by an international jury, to be auditioned in August 2018. This project involved in its construction 130 clinicians, researchers and institutional representatives, and 40 industrial partners are mobilized for its success. . This partnership is the symbol of a common ambition to bring out, on the Eurasanté campus and site of excellence, a new economic sector for the benefit of diabetic patients and all patients with chronic pathologies (cardiovascular, neurodegenerative, cancer).

“The many industrial players associated with PreciDIAB give this project all the keys to its future success. The know-how emanating from this project will be vectors of large-scale public-private R&D partnerships, and will not fail to spill over into the regional health ecosystem by making it possible, within 10 years, to host the establishment of 25 companies and create 15 start ‐ ups that the Eurasanté Bio Incubator can support in its mission to promote research ”Didier Delmotte, President of Eurasanté.

The third project concerns the implementation of a strategic tool aimed at positioning Lille as a French center of excellence for the exploitation of massive data in health: the creation of the Lille University Hospital Health Data Warehouse (EDS) . In association with INRIA Lille Nord Europe, EDS is the first step in the development of a system and an organization necessary to be a key player in artificial intelligence. The tool will serve all the thematic orientations and health concerns for the territory.

“Together, we have the common objective of preparing the future of the metropolis. With PréciDIAB, I would like us to constitute the first world research center on diabetes. Today, in our territory, we have all the assets to make this project a success. The Metropolis wants to be the architect of bringing together all these elements to create a research center from which all the companies and start-ups in our territory dedicated to these questions will benefit. The I-SITE label also recognizes and supports the region’s dynamic of excellence. The challenge, thanks to this joint mobilization, is to position the Lille metropolis among the major European cities in terms of scientific excellence but also competitiveness and international attractiveness. »Damien Castelain, President of the European Metropolis of Lille

“This partnership is emblematic of the integrated vision that we have of the development of research in the Lille metropolitan area, which must be underpinned by a collective ambition,
bringing together all the players around common objectives and with contributions
complementary in response to major societal challenges. Medical research is a factor in the international visibility of the Lille site and this partnership will make it possible to amplify the deployment of new approaches, in particular in the links between health and digital technology, generating new hypotheses which will find their concretization in large-scale clinical trials. . The IHU Precidiab will be a catalyst, as the I-site already is, of this approach carried out jointly by the University of Lille and the CHU, in conjunction with large organizations and the Institut Pasteur de Lille ”Jean‐ Christophe Camart, President of the University of Lille

The health data warehouse:
The EDS is a strategic orientation included in the project to establish the CHU de Lille. The support of the MEL will allow the significant acceleration of the constitution of a universal DHS; it is a necessary building block for current and future discussions on artificial intelligence in the territory, making it possible to integrate the use of all the data and types of health data available within the establishment. The ambitious objective is to constitute one of the main centers in France for the exploitation of big data in health. The data deposited in this DHS will be used for several purposes such as research, improving the quality of care and medico-economic analysis. This tool will help advance medical knowledge, improve the inclusion of patients in clinical trials and strengthen medical and strategic management. This strategic data will also help improve the quality of care.

Clinical Trials Platform (CTU):
The clinical research platform (PreciDIAB CTU) is a platform dedicated to diabetic patients, unique in France. It offers an integrated and adaptive organization according to the types of studies and the complexity of the research protocols.
This platform is the point of access, orientation, consultation and instruction for projects proposed by investigators, industrial and academic partners in relation to diabetic disease and its comorbidities within the framework of the IHU PreciDIAB. The main objective of the CTU is to increase the number of clinical research protocols carried out at the Lille University Hospital and in the region with all the health professionals involved in the care of the diabetic patient.

Chair of excellence:
The Lille University Hospital and the University of Lille wish to set up a Chair to support the PreciDIAB dynamic. This chair could explore three areas of potential interest for research and economic development in the Lille metropolitan area:
> Strengthening clinical and translational research in diabetes;
> Deployment of artificial intelligence in health;
> Diabetes and cognition relationship.

 

Read the full press release